Literature DB >> 19229297

Transcription and signalling pathways involved in BCR-ABL-mediated misregulation of 24p3 and 24p3R.

Zhi Sheng1, Shu-Zong Wang, Michael R Green.   

Abstract

Lipocalin 24p3 is a secreted protein that can induce apoptosis in cells containing the 24p3 cell surface receptor, 24p3R. The oncoprotein BCR-ABL activates 24p3 and represses 24p3R expression. Thus, BCR-ABL(+) cells synthesise and secrete 24p3, which induces apoptosis in normal 24p3R-containing cells but not in BCR-ABL(+) cells. The cell signalling and transcription factor pathways by which BCR-ABL misregulates expression of 24p3 and 24p3R remain to be elucidated. Here we show that BCR-ABL upregulates 24p3 expression through activation of the JAK/STAT pathway, which culminates in binding of Stat5 to the 24p3 promoter. We find that 24p3R expression is regulated by Runx transcription factors, and that BCR-ABL induces a switch in binding from Runx3, an activator of 24p3R expression, to Runx1, a repressor of 24p3R expression, through a Ras signalling pathway. Finally, we show that repression of 24p3R by BCR-ABL is a critical feature of the mechanism by which imatinib kills BCR-ABL(+) cells. Our results reveal diverse signalling/transcription pathways that regulate 24p3 and 24p3R expression in response to BCR-ABL and are directly relevant to the treatment of BCR-ABL(+) disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19229297      PMCID: PMC2670863          DOI: 10.1038/emboj.2009.35

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  43 in total

1.  Imatinib mesylate--the new gold standard for treatment of chronic myeloid leukemia.

Authors:  Karl Peggs; Stephen Mackinnon
Journal:  N Engl J Med       Date:  2003-03-13       Impact factor: 91.245

2.  Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia.

Authors:  Nicholas J Donato; Ji Y Wu; Jonathan Stapley; Hui Lin; Ralph Arlinghaus; Bharat B Aggarwal; Shishir Shishodia; Maher Albitar; Kimberly Hayes; Hagop Kantarjian; Moshe Talpaz; Shishir Shishodin
Journal:  Cancer Res       Date:  2004-01-15       Impact factor: 12.701

Review 3.  Structure and regulated expression of mammalian RUNX genes.

Authors:  Ditsa Levanon; Yoram Groner
Journal:  Oncogene       Date:  2004-05-24       Impact factor: 9.867

4.  An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia.

Authors:  A Agarwal; C A Eide; A Harlow; A S Corbin; M J Mauro; B J Druker; C L Corless; M C Heinrich; M W Deininger
Journal:  Leukemia       Date:  2008-05-29       Impact factor: 11.528

Review 5.  Biology of chronic myelogenous leukemia--signaling pathways of initiation and transformation.

Authors:  Junia V Melo; Michael W N Deininger
Journal:  Hematol Oncol Clin North Am       Date:  2004-06       Impact factor: 3.722

Review 6.  JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis.

Authors:  L S Steelman; S C Pohnert; J G Shelton; R A Franklin; F E Bertrand; J A McCubrey
Journal:  Leukemia       Date:  2004-02       Impact factor: 11.528

7.  Genome-wide analysis of gene-expression profiles in chronic myeloid leukemia cells using a cDNA microarray.

Authors:  Yasuyuki Kaneta; Yoshitoyo Kagami; Tatsuhiko Tsunoda; Ryuzo Ohno; Yusuke Nakamura; Toyomasa Katagiri
Journal:  Int J Oncol       Date:  2003-09       Impact factor: 5.650

Review 8.  Imatinib mesylate in combination with other chemotherapeutic agents for chronic myelogenous leukemia.

Authors:  Tetsuzo Tauchi; Kazuma Ohyashiki
Journal:  Int J Hematol       Date:  2004-06       Impact factor: 2.490

9.  Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.

Authors:  A Hochhaus; S Kreil; A S Corbin; P La Rosée; M C Müller; T Lahaye; B Hanfstein; C Schoch; N C P Cross; U Berger; H Gschaidmeier; B J Druker; R Hehlmann
Journal:  Leukemia       Date:  2002-11       Impact factor: 11.528

10.  BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

Authors:  Nicholas J Donato; Ji Yuan Wu; Jonathan Stapley; Gary Gallick; Hui Lin; Ralph Arlinghaus; Moshe Talpaz
Journal:  Blood       Date:  2003-01-15       Impact factor: 22.113

View more
  19 in total

1.  A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas.

Authors:  Robert B Den; Mitchell Kamrava; Zhi Sheng; Maria Werner-Wasik; Erin Dougherty; Michelle Marinucchi; Yaacov R Lawrence; Sarah Hegarty; Terry Hyslop; David W Andrews; Jon Glass; David P Friedman; Michael R Green; Kevin Camphausen; Adam P Dicker
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-06-09       Impact factor: 7.038

2.  The v-myc-induced Q83 lipocalin is a siderocalin.

Authors:  Nicolas Coudevylle; Leonhard Geist; Matthias Hötzinger; Markus Hartl; Georg Kontaxis; Klaus Bister; Robert Konrat
Journal:  J Biol Chem       Date:  2010-09-08       Impact factor: 5.157

3.  NGAL and NGALR are frequently overexpressed in human gliomas and are associated with clinical prognosis.

Authors:  Ming-Fa Liu; Tao Jin; Jin-Hui Shen; Zhong-Ying Shen; Zhi-Chao Zheng; Zeng-Liang Zhang; Li-Yan Xu; En-Min Li; Hai-Xiong Xu
Journal:  J Neurooncol       Date:  2010-12-24       Impact factor: 4.130

4.  Senescence induction in human fibroblasts and hematopoietic progenitors by leukemogenic fusion proteins.

Authors:  Narendra Wajapeyee; Shu-Zong Wang; Ryan W Serra; Peter D Solomon; Arvindhan Nagarajan; Xiaochun Zhu; Michael R Green
Journal:  Blood       Date:  2010-04-26       Impact factor: 22.113

5.  BCR-ABL suppresses autophagy through ATF5-mediated regulation of mTOR transcription.

Authors:  Zhi Sheng; Leyuan Ma; Jiaoyuan E Sun; Lihua J Zhu; Michael R Green
Journal:  Blood       Date:  2011-06-29       Impact factor: 22.113

6.  Lipocalin produced by myelofibrosis cells affects the fate of both hematopoietic and marrow microenvironmental cells.

Authors:  Min Lu; Lijuan Xia; Yen-Chun Liu; Tsivia Hochman; Laetizia Bizzari; Daniel Aruch; Jane Lew; Rona Weinberg; Judith D Goldberg; Ronald Hoffman
Journal:  Blood       Date:  2015-05-28       Impact factor: 22.113

7.  Transcription factor ATF5 is required for terminal differentiation and survival of olfactory sensory neurons.

Authors:  Shu-Zong Wang; Jianhong Ou; Lihua J Zhu; Michael R Green
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-22       Impact factor: 11.205

8.  Discovering causal signaling pathways through gene-expression patterns.

Authors:  Jignesh R Parikh; Bertram Klinger; Yu Xia; Jarrod A Marto; Nils Blüthgen
Journal:  Nucleic Acids Res       Date:  2010-05-21       Impact factor: 16.971

9.  A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications.

Authors:  Zhi Sheng; Li Li; Lihua J Zhu; Thomas W Smith; Andrea Demers; Alonzo H Ross; Richard P Moser; Michael R Green
Journal:  Nat Med       Date:  2010-05-23       Impact factor: 53.440

10.  Lipocalin 2: a multifaceted modulator of human cancer.

Authors:  Jiang Yang; Marsha A Moses
Journal:  Cell Cycle       Date:  2009-08-08       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.